ABSTRACT
Objective@#To explore the risk factors of bronchial asthma in children with allergic rhinitis, and to provide evidence for the early diagnosis, treatment and prevention of asthma in children with allergic rhinitis.@*Methods@#Children with allergic rhinitis and children with allergic rhinitis and asthma, who attended the Allergy Clinic of the Capital Institute of Pediatrics from November 2019 to October 2020, were recruited for the study. Medical history, clinical characteristics, allergen types and risk factors were collected and analyzed.@*Results@#A total of 117 children with allergic rhinitis and 111 children with allergic rhinitis that subsequently developed into asthma were included. The results of the univariate analysis showed that the occurrence of asthma in children with allergic rhinitis was associated with the course of rhinitis, severity of rhinitis, type of rhinitis, seasonal onset, history of pet contact, family history of allergic diseases, mold, ragweed, dermatophagoides culinae and dust mite sensitization( χ 2=6.15, 8.79, 3.99, 9.44, 5.17, 4.43, 8.48, 10.38, 6.18, 5.31, P <0.05). The Logistic regression analysis showed that rhinitis severity( OR = 7.03 ), family history of allergic diseases( OR =8.24), mold( OR =5.19), and household dust mite sensitization ( OR =25.25) were positively correlated with the occurrence of asthma in children with allergic rhinitis( P <0.05), and dust mite sensitization was the strongest risk factor.@*Conclusion@#The development of asthma in children with allergic rhinitis is affected by many factors, among which the severity of rhinitis, family history of allergic diseases and dust mite sensitization are the most important factors.
ABSTRACT
To observe and analyze the therapeutic efficacy of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients. A total of 180 elderly patients diagnosed as advanced breast cancer and treated at our hospital
were enrolled. All patients were randomized into study group and control group, with 90 patients in each group. Of those, capecitabine monotherapy was administered in control group, while S-1monotherapywas applied in study group.
Clinical efficacy and safety of both groups were compared. By comparing recent therapeutic effects, results showed that the overall treatment efficacy was 51.11% in study group, while the value was 35.56% in control group, suggesting a
higher therapeutic efficacy in study group [P<0.05]. Also, the incidence of side effects was significantly lower in study group compared with control group [P<0.05]. Moreover, quality of life was better preserved in study group [P<0.05]. S-1 monotherapy was relatively effective and safe in the treatment of advanced breast cancer in elderly patients